Comparative Pharmacology
Head-to-head clinical analysis: NIZORAL versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIZORAL versus POSFREA.
NIZORAL vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Biphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category C
Category C
Azole Antifungal
Azole Antifungal